Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Izzy who wrote (4642)	6/30/1998 11:22:00 AM
From: Steve Fancy	Respond to of 6136

Izzy, I think initially its being perceived as AGPH hot air. I have no opinion. I only know the stock has broken key support for the second time in a couple months and is continuing it's downslide...at least intraday has set a new low for this year. Generally initial sell-offs seem to get overdone, but technically things look lousy. I am not going to worry till I see where it ends the week, or perhaps starts next week. Does seem like a pattern is developing around AGPH and these big AIDS conferences. The pattern of insider selling and continual drop in the stock is somewhat telling also. The selling seems to have paused for May, we'll have to watch for June. Still have high hopes for Thursday and weekend press. sf

To: Izzy who wrote (4642)	6/30/1998 1:43:00 PM
From: Andreas Helke	Read Replies (1) \| Respond to of 6136

I think that Agouron wants to make sure that they are an important player in the HIV field no matter what happens. They have now licensed a PI and a NNRTI that both have different resistance profiles than the currently existing or to be introduced drugs. On the other hand they seem to de-emphasize their cancer program. I was pretty surprised that they did not issue a press release when they started the AG3340 phase II/III trial. Andreas